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Porcine circovirus type 2 (PCV2) is the primary causative agent of porcine circovirus-26 
associated disease (PCVAD). Available commercial vaccines all target the PCV2a 27 
subtype, although the circulating predominant subtype worldwide is PCV2b, and the 28 
emerging PCV2d subtype is also increasingly associated with PCVAD. Here we 29 
molecularly bred genetically-divergent strains representing PCV2a, PCV2b, PCV2c, 30 
PCV2d, and “divergent PCV2aPCV2e” subtypes by DNA-shuffling of the capsid genes 31 
to produce a chimeric virus representing PCV2 global genetic diversity. When placed 32 
in the PCV2a backbone, one chimeric virus (PCV2-3cl14) induced higher neutralizing 33 
antibody titers against different PCV2 subtypes. Subsequently, a candidate vaccine 34 
(PCV1-3cl14) was produced by cloning the shuffled 3cl14 capsid into the backbone of 35 
the non-pathogenic PCV1. A vaccine efficacy study revealed that chimeric virus PCV1-36 
3cl14 induces protective immunity against challenge with PCV2b or PCV2d in pigs. The 37 
chimeric PCV1-3cl14 virus is a strong candidate for a novel vaccine in pigs infected with 38 
variable PCV2 strains.  39 
 40 
Keywords: Porcine circovirus type 2 (PCV2); porcine circovirus-associated disease 41 



































































Porcine circovirus (PCV) is a small, non-enveloped, single-stranded DNA virus 44 
which belongs to the family Ciroviridae (1).  PCV type 1 (PCV1) was originally 45 
identified as a cell culture contaminant of the porcine kidney cell line PK-15 in the 46 
1970’s, and was later found to be non-pathogenic in pigs (2, 3).  In 1997, a pathogenic 47 
variant designated as PCV type 2 (PCV2) was identified in wasting piglets shortly after 48 
weaning (2, 4-9).  As more cases were identified worldwide, PCV2 was determined to be 49 
the primary causative agent of porcine circovirus-associated disease (PCVAD), which 50 
includes a broad spectrum of clinical symptoms such as wasting, reproductive failure, 51 
respiratory signs and enteritis, and PCV2 may also have a role in the porcine dermatitis 52 
and nephropathy syndrome (10).   53 
PCV2 is one of the most economically devastating viral pathogens to affect the 54 
global pig industry to date, and vaccination has been an effective strategy to reduce the 55 
economic losses associated with PCV2 infection (11). Currently, all commercially 56 
available inactivated or subunit vaccines target theconsist of a single PCV2a subtype 57 
capsid antigen (11-14).  However, since 2005, a new subtype, PCV2b, has taken over as 58 
the most prevalent PCV2 strain associated with PCVAD cases in the U.S. and other 59 
countries (15-17). In addition, newly emerging PCV2d strains (previously referred to as 60 
“mutant PCV2b”), have been identified in an increasing number of cases in vaccinated 61 
herds worldwide, leading to the speculation by some that the emerging PCV2d strains are 62 
able to overcome vaccine protection (18-20). A recent study showed that animals 63 
vaccinated with recombinant PCV2a capsid protein had lower viral loads and generated 64 


































































PCV2b or homologous PCV2d-1 recombinant capsid protein, suggesting that PCV2 66 
capsid immunogenicity varies (21).  However this could not fully explain how PCV2d 67 
infections are emerging in PCV2a vaccinated herds.   68 
Until recently, only three PCV2 subtypes were recognized, including PCV2a, 69 
PCV2b, and PCV2c, the last of which was identified in Denmark during the 2000’s, is 70 
recognized but not very prevalent (22, 23).  While the majority of the PCVAD cases in 71 
the United States are now associated with PCV2b, the emerging PCV2d subtype has been 72 
slowly increasing in the U.S since its initial discovery in 2012 and is now more prevalent 73 
than PCV2a (24).  Although the exact reason for the emergence of PCV2d remains 74 
unclear, it can be commonly found in vaccinated herds, leading to the speculation of 75 
either reduced protection against this emerging PCV2d or vaccination failure of 76 
individual animals (18).  While the introduction of PCV2a based vaccine strategies has 77 
resulted in a drastic decline in PCV2 prevalence (25), the increased genetic diversity of 78 
PCV2 strains is concerning, and is suggestive of selective pressure promoting genetic 79 
diversity.  In fact, a recent report has demonstrated the increasing genetic diversity 80 
amongst the PCV2d subtype, as the majority of isolates identified from 1999-2011 can be 81 
classified under the subclade “PCV2d-1,” and the majority of isolates identified recently, 82 
from 2006-2014, diverge from the PCV2d-1 subclade and are now designated “PCV2d-83 
2” (24).  In addition, in vitro evidence suggests distinct antigenic differences among 84 
PCV2 subtypes, which may help explain the emergence of new strains (26, 27). 85 
Therefore, in order to address the concern of emerging PCV2d as well as the predominant 86 
PCV2b now circulating in global swine herds, as well as the possibility for the generation 87 


































































PCV2a antigen alone, future vaccine strategies should focus on broadening the protection 89 
of a single vaccine by targeting emerging strains such as PCV2d and the predominant 90 
PCV2b subtype.   91 
DNA shuffling has been shown to be a powerful tool to introduce genetic 92 
diversity into the virus of interest (28, 29).  In fact, recently our group has successfully 93 
shuffled the structural genes of porcine reproductive and respiratory syndrome virus 94 
(PRRSV) and developed chimeric virus vaccine candidates with broadly protective 95 
properties against heterologous PRRSV strains (30-33).  Therefore, in the present study 96 
we aimed to molecularly breed by DNA shuffling the capsid genes of 5 genetically 97 
diverse PCV2 subtypes including PCV2a, PCV2b, PCV2c, PCV2d and a capsid sequence 98 
representing a recently identified divergent PCV2a virus previously referred to as 99 
“PCV2e.”    “PCV2e” The “PCV2e” genotype was (originally identified by phylogenetic 100 
analysis of the capsid sequence (34), but was later determined be included in theor 101 
divergent PCV2a genotype based on full sequence phylogenetic analysis (35)).  While the 102 
“PCV2e” strains identified are not divergent enough from PCV2a strains to be referred to 103 
as their own genotype, this strain was included in this study to increase genetic diversity 104 
of the PCV2 capsids utilized for DNA shuffling, and will be referred to as “divergent 105 
PCV2a” in this paper to separate it from the classic PCV2a strain used in this study. In  in 106 
order to create a chimeric virus that can induce broad cross-protection against different 107 
PCV2 subtypes especially the emerging PCV2d and the currently predominant circulating 108 
PCV2b.   109 
We were able to successfully generate four viable chimeric viruses with shuffled 110 


































































conducted in pigs to assess the infectivity and cross-neutralizing activities of these 4 112 
chimeric viruses. The chimeric virus (3cl14) exhibiting the highest level of cross-113 
neutralizing activity against different PCV2 subtypes were subsequently selected for a 114 
challenge and efficacy study in pigs against the currently predominant circulating PCV2b 115 
strain as well as the emerging PCV2d strain. We demonstrated that the capsid-shuffled 116 
chimeric virus 3cl14 induces protective immunity in conventional pigs against challenges 117 
with both PCV2b and PCV2d.  118 
 119 
Materials and Methods 120 
Cells:  A subclone of the PK-15 cell line that is free of PCV1 contamination was 121 
produced previously by end-point dilution of PK-15 cells (ATCC CCL-33) (36). This 122 
subclone PK-15 cell line was cultured in Minimal Essential Medium (MEM) 123 
supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics and was used in the 124 
serum virus neutralization assay and to propagate all virus stocks for this study.  125 
 126 
DNA shuffling of the capsid genes from 5 different PCV2 subtypes:  The capsid gene 127 
sequences representing each of the 5 genetically-diversified PCV2 subtypes were selected 128 
for DNA shuffling, including PCV2a (strain 40895, GenBank accession number 129 
AF264042), PCV2b (strain NC16845, accession number GU799576), PCV2c (accession 130 
number EU148503), PCV2d-1 (accession number AY181947), and “PCV2edivergent 131 
PCV2a” (accession number EF524533). The PCV2a and PCV2b strains were isolated 132 


































































“divergent PCV2aPCV2e” capsid genes were synthesized by GenScript (PIscataway, 134 
NJ).   135 
Traditional DNA shuffling was used to shuffle the 5 different PCV2 capsid genes 136 
essentially as previously described for PRRSV (31), with slight modifications. Briefly, 137 
the capsid gene DNAs from each of the five PCV2 strains were mixed in equimolar 138 
amounts with a total of 5 µg DNA and diluted in 50 µl of 50 mM Tris-HCl (pH 7.4) and 139 
10 mM MgCl2. The mixture was incubated at 15°C for 3 min with 0.15 U of DNase I 140 
(Sigma). DNA fragments ranging from 50 to 150 bp in size were purified from 2% 141 
agarose gels, and subsequently added to the Pfu PCR mixture consisting of 1X Pfu 142 
buffer, 0.2 mM each deoxynucleoside triphosphate (dNTP), and 0.06 U Pfu polymerase. 143 
A PCR program without using primers (95°C for 4 min; 40 cycles of 95°C for 30s, 60°C 144 
for 30s, 57°C for 30s, 54°C for 30s, 51°C for 30s, 48°C for 30s, 45°C for 30s, 42°C for 145 
30s, and 72°C for 2 min; and finally, 72°C for 7 min) was performed to reassemble the 146 
digested DNA fragments. Subsequently, specific primers flanking the shuffled PCV2 147 
capsid region, UniRep-F and 2aORF2-R (Table S1), were used to amplify the shuffled 148 
PCV2 capsid using Pfu Ultra II Hotstart PCR Master Mix (Agilent Technologies) per the 149 
manufacturer’s instructions (95°C for 4 min, 10 cycles of 95°C for 30s, 50°C for 30s, 150 
72°C for 30s, 25 cycles of 95°C for 30s, 54°C for 30s, 72°C for 30s, and finally 72°C for 151 
7 min). 152 
 153 
Construction of infectious DNA clones of chimeric PCV2a and PCV1 viruses with 154 
shuffled PCV2 capsid genes:  The shuffled capsid gene product libraries were cloned 155 






































































Cloning kit (Life Technologies, Carlsbad), per manufacturer’s instructions.  Selected 157 
clones were sequenced and analyzed for DNA shuffling efficiency, and well-shuffled 158 
capsid genes containing regions from all 5 PCV2 subtypes were amplified and 159 
subsequently cloned into the infectious DNA clone backbone of the PCV2a strain 40895 160 
by fusion PCR, essentially as previously described (38). Briefly, the shuffled PCV2 161 
capsids were amplified using primers UniRep-F and 2aORF2-R (Table S1). The PCV2a 162 
infectious DNA clone backbone sequence was amplified in two fragments that flank the 163 
PCV2 capsid region using primers SacII-uni-F and UniRep-R, and primers 2aORF2F and 164 
SacII-uni-R, for PCV2a fragments 1 and 2, respectively (Table S1). All three PCR 165 
reactions were performed using ACCUZYME MIX
TM 
(Bioline) at 95°C 10 min, 35 166 
cycles of 95°C for 30s, 54°C for 30s, and 68°C for 1.5 min.  The first fusion PCR was 167 
performed with the PCV2 fragment 1 and the shuffled PCV2 capsid sequence using the 168 
external primers SacII-uni-F and 2aORF2-R. Subsequently, a second fusion PCR reaction 169 
was performed with the product of the first fusion PCR reaction and the PCV2a fragment 170 
2, using the external primers SacII-uni-F and SacII-uni-R (Table S1). All fusion PCR 171 
reactions were performed using ACCUZYME MIX
TM 
at 95°C 10 min, 35 cycles of 95°C 172 
for 30s, 60°C for 30s, and 68°C for 4 min. The full-length chimeric PCV2a containing 173 
each individual shuffled PCV2 capsid was amplified, and cloned into the pCR-Blunt II 174 
TOPO plasmid using the Zero Blunt
® 
cloning kit to produce infectious DNA clones of 175 
chimeric PCV2a with shuffled capsid genes.   176 
The shuffled PCV2 capsid 3cl14 was cloned into the infectious DNA clone 177 
backbone of the non-pathogenic PCV1 to create the vaccine candidate PCV1-3cl14 by a 178 


































































using primers PCV1-BB-F and PCV1-DS-ORF2-R (Table S1). The infectious DNA 180 
clone PCV1 backbone sequence was amplified from the PBSK+ plasmid containing 181 
PCV1 in two fragments that flank the PCV1 capsid region using primers M13F (-20) and 182 
PCV-BB-R, and primers PCV-DS-ORF2-F and M13R, for PCV1 fragments 1 and 2, 183 
respectively (Table S1). All three PCR reactions were performed using Platinum® PCR 184 
Supermix (Thermo Scientific) at 94°C 3 min, 35 cycles of 94°C for 30s, 55°C for 30s, 185 
and 68°C for 1 min. Fusion PCR was performed first with the PCV1 fragment 1 and the 186 
shuffled PCV2 capsid 3cl14 fragment using the external primers M13F and PCV1-DS-187 
ORF2-R (Table S1). A second fusion PCR reaction was performed with the product of 188 
the first fusion PCR reaction and PCV1 fragment 2, using the external primers M13F and 189 
M13R.  The full-length chimeric PCV1 virus containing the shuffled capsid 3cl14 was 190 
cloned into pCR-Blunt II TOPO using the Zero Blunt
® 
cloning kit to produce the 191 
infectious DNA clone of vaccine candidate chimeric PCV1 virus 3cl14. 192 
 193 
Preparation of virus stocks:  The infectious virus stocks of PCV2b strain NC16845, U.S. 194 
PCV2d-2 strain JX535296, and each of the PCV2a capsid-shuffled chimeric viruses were 195 
produced by transfecting PK-15 cells with concatemerized viral genomes from the 196 
respective infectious DNA clones. Briefly, the respective PCV2 genomes were excised 197 
from pCR-Blunt II TOPO by SacII digestion, concatemerized, and transfected into PK-15 198 
cells to determine the viability and infectivity by immunofluorescence assay (IFA) as 199 
previously described (36, 37, 39).  The virus stocks for the chimeric PCV1-2a and 200 


































































as described above except that the viral genome was excised from the pCR-Blunt II 202 
TOPO vector by digestion with KpnI prior to concatemerization.   203 
 204 
Determination of the infectivity and cross-neutralizing activities of the PCV2 capsid-205 
shuffled viruses: To initially identify viable PCV2 capsid-shuffled viruses with improved 206 
cross-neutralizing activities against different PCV2 subtypes, we first conducted a pilot 207 
pig infection study with a limited number of animals (n=3). A total of 18, 4-week-old, 208 
cross-breed conventional pigs were purchased from a commercial farm that is known to 209 
be free of PRRSV and M. hyo without active PCV2 circulation as determined by 210 
regular PCV2 PCR on selected batches of pigs.  Sows have low amounts of antibodies 211 
against PCV2 or are seronegative and we selected litters from negative sows without 212 
cross-fostering. The piglets were randomly assigned to six groups of 3 pigs each, and 213 
each group of pigs was housed separately. Prior to inoculation, each pig was weighed, 214 
bled, and confirmed to be negative for PCV2 by PCR and serology.  Five groups were 215 
inoculated intramuscularly each with 5 ml (10
3.66 
TCID50/mL) of either chimeric virus 216 
PCV1-2a or one of the four PCV2 capsid-shuffled viruses (PCV2-3cl13, PCV2-3cl14, 217 
PCV2-3cl4-2, or PCV2-3cl12-2). One group was mock-inoculated similarly with 5 mL of 218 
PBS buffer (Table 1).  Blood was collected weekly, and animals were monitored for 219 
seroconversion to PCV2 capsid antibodies by ELISA and evidence of PCV2 infection by 220 
qPCR. Animals were necropsied at 56 days post-infection (dpi). The weekly serum 221 
samples were used to perform serum virus neutralization test against strains representing 222 
different PCV2 subtypes (data not shown for 0-49 dpi). The animal study was approved 223 



































































Serum virus neutralization assay:  Serum samples collected from infected pigs were 226 
tested for neutralizing antibody titers against the wild-type PCV2a, PCV2b, PCV2d-1, 227 
and PCV2d-2 strains by IFA.  Briefly, the serum samples were serially diluted 1:2 in PBS 228 
and mixed with 150 TCID50 of PCV2a, PCV2b, PCV2d-1, or PCV2d-2 virus stocks, 229 
respectively, at an equal volume ratio and incubated for 1 hr at 37˚C.  The serum-virus 230 
mixture was then added to PK-15 cells in a 96 well plate in duplicate.  After 72 hrs 231 
incubation at 37˚C, an IFA was preformed using pig sera against PCV2a diluted 1:1000, 232 
as the primary antibody and FITC-conjugated goat anti-pig IgG (KPL) diluted 1:50 as the 233 
secondary antibody.  The 50% serum neutralizing antibody titers were determined as the 234 
highest dilution at which there was 50% or greater reduction in virus titer compared with 235 
the average of the serum from PBS control pig group at that dilution.  236 
 237 
Vaccination efficacy and challenge study in conventional pigs:  The virus containing 238 
shuffled capsid 3cl14 in the backbone of PCV2a induced significantly higher neutralizing 239 
antibody responses against different PCV2 strains. Therefore, the shuffled capsid 240 
sequence 3cl14 was subsequently cloned into the infectious DNA clone backbone of non-241 
pathogenic PCV1 to produce a PCV1-3cl14 shuffled capsid chimeric virus as the vaccine 242 
candidate. Subsequently, a pig challenge study was conducted to evaluate the efficacy of 243 
the candidate PCV1-3cl14 chimeric virus vaccine against infection with currently 244 
predominant circulating PCV2b as well as the emerging PCV2d-2.  This experiment was 245 
a subset of a larger study.  However, wild type exposure prevented completion and 246 


































































 Briefly, a total of 32, 3-week-old, cross-breed conventional pigs were purchased 248 
from a commercial farm that is known to be free of PRRSV and M. hyopneumoniae, and 249 
is negative for PCV2.  The animal study was approved by Iowa State University IACUC 250 
as well as by Virginia Tech IACUC.  The piglets were randomly assigned to 4 groups of 251 
8 pigs each. Prior to inoculation, each pig was weighed, bled, and confirmed to be 252 
negative for PCV2.  Groups 1 and 2 pigs were each vaccinated intramuscularly (IM) in 253 
the neck region with 5 ml of the candidate PCV1-3cl14 chimeric virus vaccine (10
3.7
 254 
TCID50/mL per pig). Groups 3 and 4 pigs were each mock-vaccinated IM with 5 ml PBS 255 
buffer (Table 2).  All animals were monitored daily for clinical signs including wasting, 256 
respiratory distress, and behavioral changes such as lethargy and inappetence.  Blood 257 
samples were collected prior to inoculation, and weekly thereafter from each pig through 258 
42 days post-vaccination (dpv).  259 
At 42 dpv, groups 1 (vaccinated) and 3 (mock-vaccinated) pigs were each 260 
challenged with 10
4.8 
TCID50 (2.5 ml intranasally and 2.5ml IM) of the PCV2b NC16845 261 
virus strain, and groups 2 (vaccinated) and 4 (unvaccinated) were each similarly 262 
challenged with 10
4.8 
TCID50 of the PCV2d-2 JX535296 virus strain.  Blood samples 263 
were collected weekly through 20 days post-challenge (dpc) (or 62 dpv), at which time 264 
all pigs were weighed and necropsied. A panel of serum and tissue samples was collected 265 
for quantification of viral DNA loads and for histological examination of PCV2-266 
associated lesions.  267 
 268 
Gross pathology and histopathology evaluation:  Necropsies were performed at 20 dpc 269 


































































(ranging from 0 to 100% of the lung affected) and lymph node size (ranging from 0 271 
[normal] to 3 [four times the normal size]) were obtained for each pig (40, 41).  Sections 272 
of lung, lymph nodes (superficial inguinal, mediastinal, tracheobronchial, and 273 
mesenteric), tonsil, heart, thymus, kidney, spleen, and liver were collected during 274 
necropsy and processed routinely for histological examination and PCV2 275 
immunohistochemistry (IHC) (Iowa State University Veterinary Diagnostic Lab). Also, 276 
samples of tracheobronchial lymph node (TBLN) were collected from each pig for DNA 277 
extraction and quantification of PCV2 viral genomes by real-time quantitative PCR. 278 
Microscopic lesions in the lymphoid tissues, lungs, heart, liver, kidney, ileum, and colon 279 
were scored in a treatment status blinded manner, as described previously (40). 280 
Specifically, lymph nodes, spleen, and tonsil were evaluated for presence and degree of 281 
lymphoid depletion and histiocytic replacement. 282 
 283 
Quantitative PCR to quantify viral DNA loads in serum and tissues 284 
For both animal experiments we used a previously published protocol to extract DNA 285 
from serum and lymph node samples and a previously published qPCR SYBR green 286 
assay to quantify viral loads in these samples (37, 42).  For the pilot infection study 287 
(Table 1) and for the challenge experiment (Table 2), PCV2 specific primers were used 288 
to amplify a conserved region spanning the origin of replication and a portion of the 289 
replicase gene, as previously reported (37), using primers PCV2-83F and PCV2-83R 290 
(Table S1). For the detection of the PCV1-3cl.14 vaccine strain in the challenge study 291 
(Table 2), primers PCV1-qRepF and PCV1-qRepR primers (Table S1) were used to 292 



































































Serology:  A PCV2-specific ELISA using PCV2a capsid antigen (Iowa State University 295 
Veterinary Diagnostic Lab) was used to detect anti-PCV2 ORF2 IgG in each serum 296 
sample as previously described (43).  297 
 298 
Sequence confirmation of virus recovered from infected pigs:  DNA extracts from 299 
serum samples collected at 20 dpc from selected pigs in each group were tested by PCR 300 
for PCV2 capsid sequences, and the amplified PCR products were sequenced to verify 301 
that the virus recovered from the infected pigs was the same virus inoculated into the 302 
animals.  PCR primers Unirep-F and 2aORF-2 were used to amplify the PCV2 capsid 303 
gene in these samples using the same PCR program as described above for cloning 304 
(Table S1).  Additionally, DNA extracts of TBLN tissues from selected pigs in each 305 
group were also tested to confirm that the virus detected by PCR from infected pigs was 306 
the same virus that was inoculated into the animals.  PCV2b was amplified and 307 
sequenced using primers specific for PCV2b as previously described (37).  The  PCV2d-2 308 
vDNA was amplified and sequenced using the same forward primer as for PCV2b and a 309 
PCV2d-specific reverse primer NB-56-m2b (Table S1). 310 
 311 
Statistical Analysis:  Statistical analysis was performed using Prism v6.0 (Graphpad, La 312 
Jolla CA).  A one-tailed t-test was used to analyze statistical significance between two 313 
groups, while a one-way ANOVA and then t-tests corrected for multiple comparisons 314 




































































Generation of infectious chimeric viruses containing the shuffled capsid from 5 318 
genetically distinct PCV2 strains:  Traditional DNA shuffling was used to molecularly 319 
breed the capsid genes from five genetically distinct PCV2 strains representing different 320 
subtypes PCV2a PCV2b, PCV2c, and PCV2d-1, as well as “divergent PCV2aPCV2e” 321 
(divergent PCV2a) (Fig. 1).  Although the general consensus is that previously classified 322 
“divergent PCV2aPCV2e” virus isolates do not diverge enough from identified PCV2a 323 
strains to be considered their own subtype (35), a “divergent PCV2aPCV2e” capsid 324 
sequence was chosen to help increase the genetic diversity of the resulting shuffled 325 
capsid.  The capsid gene sequences from these 5 strains were shuffled using DNase I 326 
digestion and reassembled by PCR without primers. A PCR product of the expected size 327 
was then generated after a second round of PCR with specific primers spanning the 328 
capsid gene.   The shuffled capsid gene library was then cloned into the infectious clone 329 
backbone of PCV2a (strain 40985) to screen for viable viruses.  Of the more than 50 330 
clones with “well-shuffled” capsids (containing regions from all 5 parental PCV2 331 
strains), only 4 of them successfully rescued infectious virus when transfected into PK-15 332 
cells (data not shown).  333 
The four viruses with shuffled capsids contain a range of combinations of the 334 
genetic signatures of PCV2 genomes from all 5 parental strains (Fig. 1). The majority of 335 
the unique amino acid signatures introduced into the shuffled capsids originated from 336 
PCV2c, which is not surprising since PCV2c is the most genetically distinct of the 5 337 


































































here that traditional DNA shuffling successfully generated viable infectious chimeric 339 
viruses with shuffled capsid genes from 5 different PCV2 subtypes.  340 
 341 
PCV2-3cl14 with shuffled capsid genes induces cross-neutralizing antibodies against 342 
different PCV2 subtypes:  To determine the viability and screen for the best virus with 343 
shuffled capsids for subsequent challenge and efficacy study, we experimentally infected 344 
conventional pigs with each of the four viruses (PCV2-3cl13, PCV2-3cl14, PCV2-345 
3cl4_2, and PCV2-3cl12) as well as with the chimeric PCV1-2a virus (12). Serum 346 
samples were collected prior to infection and weekly thereafter, and all animals were 347 
monitored for serconversion to PCV2a capsid by an ELISA (Table 1). All animals 348 
experimentally inoculated with PCV1-2a or with PCV2-3cl14 seroconverted to PCV2 349 
antibodies by 49 days post-inoculation (dpi), however only 2 out of 3 animals in the 350 
PCV2-3cl12_2 and 1 of 3 pigs inoculated with either virus PCV2-3cl4 or PCV2-3cl4_2 351 
were seropositive at 49 dpi (Table 1). 352 
Serum samples collected from 56 dpi were tested by a serum virus neutralization 353 
assay in PK15 cells for cross-neutralizing antibodies against wild-type PCV2a, PCV2b, a 354 
PCV2d-1, and PCV2d-2 virus strains (Fig. 3). The neutralization assay was not 355 
performed against the parental PCV2c and divergent PCV2aPCV2e strains because 356 
PCV2c viruses have not associated with PCV2-induced disease and attempts to grow the 357 
divergent PCV2aPCV2e wild type virus in PK-15 cells was unsuccessful in our hands 358 
(data not shown).  Infections of pigs with 3 PCV2 viruses with shuffled capsid genes 359 
(PCV2-3cl13, PCV2-3cl4_2, and PCV2-3cl12) did not induce higher levels of 360 


































































for the current Fostera
TM
 PCV commercial vaccine.  However, infection of pigs with the 362 
chimeric virus PCV2-3cl14 with shuffled capsid genes from different PCV2 subtypes 363 
induced significantly higher neutralizing antibody titers against PCV2a and PCV2d-2 364 
when compared to PCV1-2a (p<0.05) (Fig. 3). In addition, although not statistically 365 
significant, the chimeric virus PCV2-3cl14 also induced higher levels of neutralizing 366 
antibody than the PCV1-2a against both PCV2b and PCV2d-2.  Taken together, this pilot 367 
animal study suggests that the viruses with shuffled capsid genes are viable and 368 
infectious in pigs, and that one shuffled capsid virus PCV2-3cl14 induces significantly 369 
higher levels of neutralizing antibodies against genetically distinct PCV2 strains when 370 
compared to the other chimeric viruses as well as to the PCV1-2a vaccine virus. 371 
Therefore, the virus PCV2-3cl14 was selected for the subsequent challenge and efficacy 372 
study in pigs to evaluate its potential use as a novel vaccine.  373 
 374 
The chimeric virus PCV1-3cl14 induces protective immunity in conventional pigs 375 
against challenge with PCV2b and PCV2d-2.  PCV2a is the genomic backbone for the 376 
virus PCV2-3cl14. Therefore, in order to produce a novel vaccine candidate, we 377 
subsequently transferred the shuffled capsid gene from the virus PCV2-3cl14, identified 378 
in the initial cross-neutralization study, to the genomic backbone of the non-pathogenic 379 
PCV1 to produce a new chimeric virus PCV1-3cl14 with a shuffled capsid.  To assess 380 
whether the chimeric virus PCV1-3cl14 vaccine candidate protects against challenge with 381 
different PCV2 subtypes, two groups of pigs (n=8) were each vaccinated with the PCV1-382 
3cl14 chimeric virus, and another two groups of pigs (n=8) were mock-vaccinated with 383 


































































monitored for seroconversion to PCV2 capsid antibody.  At 42 days post-vaccination, one 385 
group of vaccinated and one group of mock-vaccinated animals were challenged with the 386 
predominant field strain PCV2b currently circulating in swine herds worldwide. 387 
Similarly, one vaccinated group and one mock-vaccinated group of pigs were challenged 388 
with the emerging PCV2d-2 virus.  Blood samples were taken weekly after challenge and 389 
all animals were necropsied at 20 dpc.   390 
As expected, pigs in the two vaccinated groups started to seroconvert to PCV2 391 
capsid antibody by 42 dpv, whereas mock-vaccinated groups did not seroconvert until 7-392 
14 dpc with PCV2b or PCV2d-2 (or 49 or 56 dpv, Table 2, Fig. 4). A qPCR assay 393 
targeting the PCV1 replicase gene (ORF1) was used to test for PCV1-3cl14 viral DNA 394 
from weekly sera, but PCV1-3cl14 viral DNA was undetectable and below the detection 395 
limit of the assay in any group after vaccination (data not shown). This is consistent with 396 
previous reports of the attenuated chimeric PCV1-2 virus infections in pigs (12, 37).   397 
Only 2 out of 8 animals vaccinated and subsequently challenged with PCV2b had 398 
detectable viremia, and only at 14 dpc, compared to 4 and 7 out of 8 PCV2b challenge 399 
control animals at 14 and 20 dpc, respectively (Table 2).  This difference was statistically 400 
significant, as the vaccinated and PCV2b challenged group had significantly lower levels 401 
of viral DNA loads in sera at 20 dpc, compared to mock-vaccinated and PCV2b 402 
challenged animals (p<0.01) (Fig. 5). For animals vaccinated and subsequently 403 
challenged with PCV2d-2, 1/8 at 14 dpc and 2/8 at 20 dpc had detectable viremia, while 404 
7/8 PCV2d-2 challenged control animals were positive for serum viral DNA at 14 dpc 405 
and 20 dpc (Table 2). Also, the vaccinated and PCV2d-2 challenged group had serum 406 


































































respectively), as compared to PCV2d-2 challenge only controls (Fig. 5).  All vaccinated 408 
and subsequently challenged groups had significantly lower levels of PCV2 viremia at 409 
the peak of virus replication compared to control groups. In addition, all vaccinated and 410 
subsequently challenged groups had significantly lower levels of detectable PCV2 DNA 411 
in lymph nodes compared to mock-vaccinated and challenged groups (PCV2b = p<0.001, 412 
PCV2d-2 = p<0.0001, Fig. 6). These results indicated that vaccination with PCV1-3cl14 413 
chimeric virus significantly reduces the level of virus replication in pigs when challenged 414 
with the predominant PCV2b subtype or with an emerging PCV2d-2 strain.  415 
In addition to reducing viral DNA loads in sera and lymphoid tissues, vaccinated 416 
animals also had a decreased PCVAD lesion score compared to unvaccinated animals 417 
(Fig. 7). Vaccinated pigs that were subsequently challenged with PCV2b had 418 
significantly reduced pathological lesion scores for all measures of PCVAD, which 419 
includes lymphoid depletion and histiocytic replacement in lymph nodes, spleen, and 420 
tonsil tissues, as compared to unvaccinated but PCV2b challenged controls (Fig. 7). 421 
Similarly, pigs vaccinated and subsequently challenged with PCV2d-2 had significantly 422 
lower pathological lesion scores for lymph node measures, as well as tonsil lymphoid 423 
depletion (Fig. 8A, 8B, 8E) as compared to unvaccinated but PCV2d-2 challenged 424 
controls. Consistent with the results for serum and lymph node viral DNA detection, both 425 
vaccinated and subsequently challenged groups had significantly lower viral antigen 426 
scores in lymph node, spleen, and tonsil, compared to challenge only controls (Fig. 8). 427 
Overall, these results suggest that vaccination with PCV1-3cl14 chimeric virus vaccine 428 


































































predominant PCV2b subtype currently circulating in pig farms worldwide and the 430 
emerging PCV2d-2 strain.  431 
 432 
Discussion 433 
PCVAD is arguably one of the most economically-important diseases affecting 434 
the global swine industry. Characterized by progressive wasting, hallmark histological 435 
lesions of lymphoid depletion with histiocytic infiltration, and the presence of PCV2 436 
antigen or DNA in the lesions, PCVAD is caused by PCV2 infection, although co-437 
infection with other pathogens are usually necessary for the development of the full-438 
spectrum of clinical PCVAD (44-46). Several commercial vaccines against PCV2 are 439 
currently available, all of which are based on the PCV2a subtype (11), which prior to 440 
2005 was the main subtype (15-17).  However, now PCV2b has surpassed PCV2a as the 441 
most prevalent strain associated with PCVAD losses in the swine industry (15-17). In 442 
addition, recently, speculation of vaccination failures has been reported, and though no 443 
direct evidence has been found as of yet, these Andl though all current vaccines have 444 
been proven effective at preventing clinical signs and global economic loss due to 445 
PCVAD, events have been associated with the emergence of the PCV2d (or mutant 446 
PCV2b) subtype (18, 19, 24), as well as the replacement of PCV2a with PCV2b as the 447 
predominant circulating subtype, cannot be ignored.   (18, 19, 24). Therefore, it is logical 448 
to develop the next generation of vaccines especially against the emerging PCV2 strains.  449 
The objectives of this study were to molecularly breed the capsid genes from 450 
different PCV2 subtypes by DNA shuffling, and to develop a candidate chimeric virus 451 


































































divergent PCV2 subtypes. Traditional DNA shuffling approach was undertaken in this 453 
study, in which 5 genetically distinct capsid sequences from each of the 4 known PCV2 454 
subtypes, as well as from the “divergent PCV2aPCV2e” type (47), which is now 455 
generally considered as a divergent PCV2a strain (35), were used for the DNA shuffling. 456 
Of the more than 50 shuffled PCV2 capsids that were cloned and sequenced, infectious 457 
chimeric viruses were rescued in PK15 cells only in 4 of them, suggesting that the small 458 
PCV2 genome cannot support a large number of forced random reassortment within the 459 
capsid gene.   460 
The four viable viruses with shuffled PCV2 capsids generated by traditional DNA 461 
shuffling contained antigenic epitopes from all 5 genetically divergent PCV2 strains, 462 
although most of the variability in the shuffled capsids could be found in the PCV2c 463 
parental strain. This was not unexpected, as the PCV2c subtype is the most divergent 464 
strain from the rest of the PCV2 subtypes identified thus far, based on a phylogenetic 465 
analysis (24, 48). Alignment of the 5 selected parental strains revealed that the PCV2c 466 
does, in fact, contain the most genetically distinct amino acid variations, though some of 467 
these amino acids overlap with the parental PCV2d strain, including the addition of a 468 
terminal lysine residue.  The presence of amino acid residues unique to PCV2c and 469 
PCV2d strains suggests that, although the PCV2c subtype has not associated with any 470 
clinical disease, this subtype could possibly have contributed to the evolutionary 471 
emergence of the current PCV2d subtype. In fact, the PCV2c subtype was recently 472 
isolated from feral pigs in Brazil for first time since it was originally described in 473 
Denmark in the early 90s.  The feral pig populations were also infected with the other 474 


































































findings support the inclusion of PCV2c for DNA shuffling in the current study in order 476 
to increase the breadth of protection of the resulting candidate vaccine against currently 477 
emerging and future possible emerging PCV2 strains.   478 
In order to determine the in vivo infectivity of the shuffled viruses and to screen 479 
for the best chimera for subsequent challenge and efficacy study, conventional pigs were 480 
experimentally inoculated in a pilot study with each of the 4 viruses with shuffled capsids 481 
in the PCV2a backbone as well as with the chimeric PCV1-2a vaccine virus (12).  The 482 
results showed that virus PCV2-3cl.14 induced higher levels of neutralizing antibody 483 
titers when compared to the chimeric PCV1-2a virus, as well as the other 3 shuffled 484 
capsid viruses. The chimeric virus PCV2-3cl.14 also induced significantly higher 485 
neutralizing antibody titers against PCV2a and PCV2d-2 strains.  The fact that the PCV2-486 
3cl1.14 shuffled capsid virus induced higher neutralizing antibody titers against PCV2a 487 
compared to a homologous vaccination with the PCV1-2a chimeric vaccine strain was 488 
unexpected.  However others have demonstrated this phenomenon with PCV2 viruses 489 
before.   Although they demonstrate opposing results, there are many differences in the 490 
experimental design, which could explain these discrepenciesdiscrepancies (21, 49). In 491 
addition, the PCV2-3cl14 virus strain grew to the lowest titer of 10^3.33 TCID50/mL 492 
compared to the other PCV2-shuffled capsid strains and the PCV1-2a vaccine strain in 493 
vitro on multiple occasions (data not shown), suggesting that the increase in total and 494 
breadth of neutralizing antibody titers compared to the other strains tested was not simply 495 
due to increased replication efficiency.  Taken together, these results demonstrate that 496 
more research is needed to understand the complicated nature of PCV2 capsid 497 



































































to the other three shuffled capsids as well as the PCV1-2a reveals three regions with 499 
distinct amino acid residues.  Two of these regions, amino acids 106-108 and 126, 500 
overlap with previously-identified B-cell antigenic epitopes (50). In addition, the 501 
mutation at position 126 corresponded to a location within the predicted B-cell and SLA-502 
class II epitopes (51).  It is also possible that mutations within regions unrecognized as 503 
immunogenic may play a direct role in the protective immune response, or alter structural 504 
recognition of other immunogenic capsid regions, such as the 169-180 region shown to 505 
play a “decoy” role in anti-PCV2 antibody recognition (52, 53).  While the 3cl14 residues 506 
at 169-180 are identical to the strain used to demonstrate the decoy nature of this region, 507 
changes at other locations may result exposure of this region to antibody neutralization.  508 
While the majority of PCV2c amino acid residues introduced into the 3cl14 shuffled 509 
capsid residues that map to a subset of the parental strains, but not one distinct subtype 510 
have been introduced.  The 3cl14 sequence contains amino acids at positions 14 and 232 511 
that represent the PCV2a and “divergent PCV2a” as well as an amino acid residue that is 512 
shared by PCV2d, PCV2b, and PCV2, but not divergent PCV2a or PCV2c at position 21, 513 
and a residue shared by the parental PCV2b and PCV2d but not PCV2c, PCV2a, or 514 
“divergent PCV2a” at position 185.  Interestingly, the 3cl13, 3cl4_2, and 3cl12_2 515 
shuffled capsids all contain the additional lysine residue at the C-terminus of the capsid 516 
found in the PCV2d parental strain.  This mutation is suggested to play a role in the 517 
increased pathogenicity and vaccine failure of the emerging PCV2d strains, although no 518 
direct evidence of this role has been reported to date (38, 54). However, the 3cl14 519 
shuffled capsid sequence does not include the additional lysine, suggesting that it is not a 520 
necessary epitope for producing neutralizing antibodies against the PCV2d-2 strains, 521 
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since PCV1-3cl14 protects against PCV2d-2 infection in the challenge and efficacy 522 
experiment. While it is possible that the properties of 3cl14 capsid sequence discussed 523 
above are important for production of cross-protective neutralizing antibodies in pigs, 524 
additional research is warranted to determine the important amino acid residues that may 525 
play a critical role in conferring cross-neutralizing activities against different PCV2 526 
subtypes. 527 
Based on induction of significantly higher cross-neutralizing antibody titers, 528 
compared to the other shuffled capsid candidates, the shuffled 3cl14 capsid sequence was 529 
subsequently selected to produce a chimeric virus PCV1-3cl14 vaccine candidate.  The 530 
protective efficacy of the PCV1-3cl14 chimeric virus as a potential vaccine was evaluated 531 
by challenging vaccinated pigs with PCV2b or PCV2d, respectively. PCV2b is the 532 
predominant subtype currently infecting pigs worldwide, whereas the PCV2d is an 533 
emerging subtype (24).  We previously have demonstrated the attenuation of chimeric 534 
PCV1-2a and PCV1-2b viruses in the genomic backbone of the non-pathogenic PCV1 in 535 
vivo (12, 37, 39).  Consistent with these previous reports, there was no detectable PCV1-536 
3cl14 viremia in vaccinated pigs throughout the duration of the study, and no detectable 537 
clinical disease prior to challenge with either PCV2b or PCV2d (data not shown), even 538 
though the vaccinated pigs are infected as evidenced by seroconversion to PCV2 capsid 539 
antibody. It is also possible that the standard PCV2a capsid- based PCV2 ORF2 ELISA 540 
assay is less sensitive for detection of the PCV1-shuffle capsid induced antibodies, 541 
possibly leading an underrepresentation of the antibody titers in the PCV1-3cl14 542 
vaccinated groups, however further research is needed to determine if this is the case.  543 


































































reduction in challenge virus levels shows a significant effect of vaccination with the 545 
PCV1-3cl14 vaccine candidate on PCV2b and PCV2d challenge strains.    546 
Vaccination with the chimeric virus PCV1-3cl14 vaccine candidate resulted in 547 
significantly reduced PCV2b or PCV2d viral DNA loads at the peak of viremia as well as 548 
reduced viral DNA loads in lymphoid tissues at termination of the study. Furthermore, 549 
the lymphoid lesions were also significantly reduced in vaccinated groups subsequently 550 
challenged with PCV2b compared to mock-vaccinated and challenged controls. Though 551 
the vaccinated animals showed no statistically significant reduction in spleen lymphoid 552 
depletion and spleen and tonsil hystiocytic replacement when challenged with PCV2d, 553 
they did have significant reduction for the rest of the PCVAD-associated scores, as well 554 
as reduced viral DNA loads in serum and lymph node tissues, indicating that the PCV1-555 
3cl14 chimeric virus vaccine candidate induced protection against both PCV2b and 556 
PCV2d challenge in conventional pigs.   557 
 558 
Conclusion 559 
To our knowledge, this is the first report of construction of viable chimeric PCV2 560 
vaccine candidate by shuffling the capsid gene of 5 divergent PCV2 strains belonging to 561 
different subtypes.  Importantly, vaccination of pigs with a chimeric virus PCV1-3cl14 562 
with shuffled capsid genes induced protective immunity against challenge with the 563 
predominant PCV2b subtype and the emerging PCV2d subtype. Therefore, this chimeric 564 
virus is a potential candidate for further development into the next generation of vaccine 565 
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Fig. 1. Amino acid sequence alignment of the capsid proteins from the five parental 
PCV2 wild-type strains and the four candidate DNA-shuffled capsids evaluated in 
this study. The first five sequences represent the parental strains including PCV2a (strain 
40895, GenBank accession number AF264042), PCV2b (strain NC16845, accession 
number GU799576), PCV2c (accession number EU148503), PCV2d (accession number 
AY181947), and “divergent PCV2a” (accession number EF524533). while the bottom 
four sequences represent the DNA-shuffled PCV2 capsids.  Amino acids that differ from 
the consensus are shown in black.  
 
Fig. 2. A phylogenetic tree of the capsid genes of selected PCV2 strains from 
different subtypes. The phylogenetic tree was constructed using the neighbor-joining 
method with bootstraps in 1,000 replicates. The number above each major branch 
indicates the bootstrap value. The bold italicized sequence names represent the PCV2 
sequences of the 5 parental strains used for DNA shuffling in the study.   
 
Fig. 3. Comparison of 50% neutralizing antibody titers against four PCV2 wild-type 
strains from sera of pigs experimentally inoculated with chimeric viruses PCV2-
3cl13, PCV2-3cl14, PCV2-3cl4_2, and PCV2-3cl12_2, or PCV1-2a with shuffled 
capsid genes.   In vitro 50% neutralization assay of respective sera collected at 56 days 
post-infection against three parental PCV2 strains: (A) PCV2a, (B) PCV2d-1, (C) 
PCV2b, and (D) PCV2d-2 isolate. The NA titers were calculated as the highest 2-fold 
dilution (2
n


































































of positive fluorescent foci, compared to the serum samples from the mock (PBS) 
inoculated control group in the same dilution. Asterisk (*) sign indicates p<0.05 analyzed 
using one-way ANOVA. 
 
Fig. 4. PCV2 capsid-specific antibody response in conventional pigs experimentally 
inoculated with the chimeric virus PCV1-3cl14 vaccine candidate and challenged 
with the wild-type virus strains PCV2b or PCV2d-2.   The mean S/P ratio ± SEM is 
plotted for each treatment group throughout the duration of the study. The virus challenge 
took place at 42 days post-vaccination (dpv).  The dashed line at 0.2 S/P ratio denotes the 
lower end cutoff for a positive sample in this assay. 
 
Fig. 5. Quantification of PCV2 viral DNA loads in sera from pigs vaccinated with 
the chimeric PCV1-3cl14 virus and subsequently challenged with PCV2b or PCV2d-
2 compared to challenge only controls.  Quantification of PCV2 ORF1 viral DNA loads 
in sera using qPCR in (A) PCV2b challenged and (B) PCV2d-2 challenged animals.  
Group means ± SEM are plotted for each time point post-challenge.  The limit of 
detection for the assay was 10
4.2
 copies/mL serum of ORF1 DNA determined by a 




 copies of the wild-type PCV2b genome.  (*) Indicates 
statistical significance between groups (Student’s t-test, corrected for multiple tests).  
 
Fig. 6: Quantification of PCV2 viral DNA loads in lymph nodes from pigs 
vaccinated with the chimeric PCV1-3cl14 virus and challenged with PCV2b or 


































































DNA loads in lymph nodes using qPCR in (A) PCV2b challenged (B) and PCV2d-2 
challenged animals.  Group means ± SEM are plotted for each time point post-challenge.  
The limit of detection for the assay was 10
7.1
 copies/mg tissue of ORF1 viral DNA, as 




 copies of the wild-type PCV2b genome.  
(*) Indicates statistical significance between groups at that time point (Student’s t-test, 
corrected for multiple tests).  
 
Fig. 7. Comparison of lymphoid tissues in pigs vaccinated with the chimeric PCV1-
3cl.14 virus and subsequently challenged with PCV2b or PCV2d-2 with those of 
challenge only controls. Lymphoid depletion and histiocytic replacement for (A, B) 
lymph nodes, (C, D) spleen, and (E, F) tonsils at necropsy were compared for vaccinated 
and challenged animals () with those of challenge only controls (). Individual animal 
scores are represented by individual symbols and group means ± SEM are displayed. 
Asterisk (*) sign indicates statistically significant differences between groups (student’s 
t-test).  
 
Fig. 8. Quantification of PCV2 viral antigen in lymphoid tissues by PCV2 
immunohistochemistry (IHC). The tissues were obtained from pigs vaccinated with 
the chimeric PCV1-3cl.14 virus and subsequently challenged with PCV2b or 
PCV2d-2 compared to challenge only controls. PCV2 viral antigen scores determined 
for (A) lymph nodes, (B) spleen, and (C) tonsils at necropsy were compared for 
vaccinated and challenged animals () with those of challenge only controls (). 


































































are displayed.  Asterisk (*) sign indicates statistically significant differences between 
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Tonsil - Viral Antigen IHC
** **
A B C
Table 1. Seroconversion to PCV2-specific antibodies in pigs experimentally infected with chimeric PCV2 
viruses containing shuffled capsids or with the PCV1-2a vaccine virus 
 
Group Inocula 




0 7 14 21 28 35 42 49 
1 PCV2-3cl13 0/3 0/3 0/3 0/3 0/3 1/3 2/3 1/3 
2 PCV2-3cl14 0/3 0/3 0/3 0/3 1/3 3/3 3/3 3/3 
3 PCV2-3cl4_2 0/3 0/3 0/3 0/3 0/3 1/3 1/3 1/3 
4 PCV2-3cl12_2 0/3 0/3 0/3 0/3 0/3 1/3 1/3 2/3 
5 PCV1-2a 0/3 0/3 0/3 0/3 1/3 2/3 3/3 3/3 
6 PBS 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 
          
          
a 
PCV2 antibody was measured at different days post-inoculation (DPI) with an ELISA using the recombinant PCV2 capsid protein as the antigen.  Animals 





Table 2. Seroconversion to PCV2-specific antibodies by ELISA and detection of viremia by PCR in pigs vaccinated with PCV1-3cl14 virus and challenged with 
PCV2b or PCV2d-2 
 
Group Vaccine Challenge Virus 






No. of pigs positive for 

















 0/8 0/8 0/8 0/8 1/8 3/8 3/8 
 
7/8 8/8 8/8 
 






0/8 0/8 0/8 0/8 0/8 2/8 4/8 
 
5/8 5/8 5/8 
 






0/8 0/8 0/8 0/8 0/8 0/8 0/8 
 
2/8 5/8 8/8 
 






0/8 0/8 0/8 0/8 0/8 0/8 0/8  1/8 4/8 6/8  1/8 7/8 7/8 
a 
PCV2 antibody was measured with an ELISA with the recombinant PCV2 capsid antigen.  Animals were considered to have seroconverted when samples from two or more consecutive time 
points were seropositive 
b
 Results represent detection by real-time PCR of  wild-type PCV2 DNA 
c 




Table S1: Oligonucleotide primers used in this study 











PCV2-83F AAAAGCAAATGGGCTGCTAA  
PCV2-83R TGGTAACCATCCCACCACTT 
PCV1 qRepF  TGGAGAAGAAGTTGTTGT 
PCV1 qRepR  TCTACAGTCAATGGATACC 
	  
Supplementary Table 1
